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Lymphoedema management to prevent acute 
dermatolymphangioadenitis in podoconiosis in northern 
Ethiopia (GoLBeT): a pragmatic randomised controlled trial
Henok Negussie*†, Meseret Molla*, Moses Ngari, James A Berkley, Esther Kivaya, Patricia Njuguna, Greg Fegan, Abreham Tamiru, 
Abebe Kelemework, Trudie Lang, Melanie J Newport, Andy McKay, Fikre Enquoselassie, Gail Davey
Summary
Background Podoconiosis (also known as endemic, non-filarial elephantiasis) affects about 4 million subsistence 
farmers in tropical Africa. Poor awareness of the condition and inadequate evidence for the efficacy of treatment mean 
that no government in an endemic country yet offers lymphoedema management for patients with podoconiosis. 
Among patients with filarial lymphoedema, trials suggest that limb care is effective in reducing the most disabling 
sequelae: episodes of acute dermatolymphangioadenitis. We aimed to test the hypothesis that a simple, inexpensive 
lymphoedema management package would reduce the incidence of acute dermatolymphangioadenitis in adult 
patients with podoconiosis in northern Ethiopia. 
Methods We did a pragmatic randomised controlled trial at health posts and health centres in 18 sub-districts of 
Aneded woreda (district) in Amhara, northern Ethiopia. Participants were adults aged 18 years and older, had a 
diagnosis of at least stage 2 podoconiosis (persistent lymphoedema) and a negative antigen test for filariasis, and 
intended to remain within Aneded woreda for the duration of the trial. Patients were randomly assigned (1:1) to either 
receive a package containing instructions for foot hygiene, skin care, bandaging, exercises, and use of socks and 
shoes, with support by lay Community Podoconiosis Agents at monthly meetings (intervention group) or to receive 
no intervention (control group). Participants were aware of their group assignment, but researchers doing all analyses 
were masked to treatment group. The primary outcome was incidence of acute dermatolymphangioadenitis episodes 
in the total period of observation of each participant, measured by use of validated patient self-reported pictorial 
diaries. This trial was registered with the International Standard Randomised Controlled Trials Number Register, 
number ISRCTN67805210.
Findings Between Dec 1, 2014, and June 30, 2015, 1339 patients were screened, and 696 patients were enrolled and 
randomly allocated to treatment groups. We allocated 350 patients to the intervention group and 346 patients to the 
control group. 321 (92%) patients from the intervention group and 329 (95%) patients from the control group pro vided 
follow-up results at 12 months. During the 12 months of follow-up, 16 550 new episodes of acute 
dermatolymphangioadenitis occurred during 765·2 person-years. The incidence of acute dermatolymphangioadenitis 
was 19·4 episodes per person-year (95% CI 18·9–19·9) in the intervention group and 23·9 episodes per person-year 
(23·4–24·4) in the control group. The ratio of incidence rate in the intervention group to that of the control group was 
0·81 (0·74 to 0·89; p<0·0001), with a rate difference of –4·5 (–5·1 to –3·8) episodes per person-year. No serious adverse 
events related to the intervention were reported.
Interpretation A simple, inexpensive package of lymphoedema self-care is effective in reducing the frequency 
and duration of acute dermatolymphangioadenitis. We recommend its implementation by the governments of endemic 
countries.
Funding Joint Global Health Trials scheme (from the Wellcome Trust, the UK Medical Research Council, and UK Aid).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Podoconiosis is a form of lymphoedema that arises in 
tropical highland areas in genetically susceptible people 
who do not use footwear.1,2 This disease is an important 
problem in tropical Africa, where irritant volcanic soils 
that are rich in silicates have been generated by the 
environmental conditions of high altitude (>1000 m) and 
high rainfall (>1000 mm per year), and these soils are 
farmed by very poor people who cannot afford shoes or 
water for washing.3 In affected individuals, mineral 
particles penetrate the skin, which is characterised by 
low hydration of the stratum corneum,4 and these 
particles are taken up by macrophages in the dermis, 
afferent lymphatic vessels, and lymph nodes. The 
primary lymphatic vessels become dilated and 
surrounded by lymphocytes as oedema and disorganised 
collagen prod uction occurs. If fibrosis predominates, the 
lymphatic lumen narrows and is eventually destroyed; if 
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oedema predominates, lymphatic valvular dysfunction 
tends to occur.5
Although rarely a direct cause of mortality, podoconiosis 
disables an estimated 4 million subsistence farmers in 
tropical Africa; this disease reduces productivity6 and 
leads to substantial stigmatisation by the community7–9 
and by health professionals,10 low quality of life,11 
and depression.12 Episodes of acute dermatolymph­
angioadenitis are among the most severe clinical 
consequences of lymphoedema. The causes of acute 
dermato lymphangioadenitis among patients with 
podoconiosis are likely to be similar to its causes among 
patients with other types of lymphoedema, such as filarial 
or post­surgical lymphoedema. Episodes of acute 
dermatolymphangioadenitis are characterised by malaise, 
fever, chills, diffuse inflammation, swelling of the limbs, 
lymphangitis, adenitis and, eventually, skin peeling.13 
These episodes are known locally as “michader”. They 
occur frequently (reports vary from five to 23 episodes per 
year), and contribute substantially to the dis ability and 
social effects associated with podoconi osis.12,14–16 Antibiotic 
therapy (including penicillin), which has been rec­
ommended for interruption of acute dermato lymph­
angio adenitis episodes,17 is not routinely avail able for 
patients in remote rural populations in Ethiopia. Despite 
the high impact of podoconiosis on rural farming 
communities, treatment and con trol of podoconiosis 
have been ham pered by mis diagnosis (chiefly, 
confusion with filarial lymphoedema) and fatalism.10
In Ethiopia, where 1·5 million people are affected by 
podoconiosis,18 foot care has been offered to people 
with podoconiosis through small non­government 
organisations in some areas of the three most heavily 
affect ed regions: Amhara, Oromia, and Southern 
Nations Nationalities and Peoples regions. This local, 
so­called bottom­up innovation19 has developed from 
the grassroots level with little formal evaluation. To date, 
two small studies20,21 have assessed foot hygiene in podo­
coniosis: an uncontrolled follow­up study20 showed clini­
cal improvements and improvements to quality of life 
associated with food hygiene practice and a trial21 that 
used small volumes of water with glycerol showed 
equivalent effects on skin barrier function to treatment 
with larger volumes of water. Evidence of the effects of 
lymphoedema management on prevention of acute 
dermatolymphan gio adenitis, the most disabling con­
sequence of podo coniosis lymphoedema, is unavailable. 
Thus, there is an urgent need for evidence on which to 
base national and international policy.
Among individuals with filarial lymphoedema, obser­
vational studies22–24 have shown that lymphoedema care is 
effective in reducing the incidence of acute dermato­
lymphangio adenitis, disease stage, and disability. To our 
know ledge, evaluation of similar care on the incidence 
of acute dermatolymphangioadenitis in podoconiosis 
lympho edema has not been done. In GoLBeT (the Gojjam 
Lymphoedema Best Practice Trial), we tested the 
hypothesis that a simple lymphoedema treatment package 
(comprising information about foot hygiene, skin care, 
bandaging, exercises to improve lymph drainage, and use 
of socks and shoes) would reduce the incidence of acute 
dermatolymphangioadenitis.
Methods
Study design and participants
We did a pragmatic, randomised controlled trial at health 
posts and health centres in 19 kebeles (sub districts) of 
Aneded woreda (district) in the Amhara region of 
northern Ethiopia. The trial protocol has been published 
previously.25 Participants were adults aged 18 years or 
Research in context
Evidence before this study
We did a search of PubMed and Google with the search terms 
“podoconiosis” and “non-filarial elephantiasis”, and we 
manually searched the reference lists of articles identified. The 
search was from the beginning of time until April 20, 2016, 
and included all articles in English, French, and Spanish. 
Two studies on management of podoconiosis lymphoedema 
have been done. The first of these studies was an uncontrolled 
follow-up study of 30 patients with podoconiosis for 1 year, 
which found reductions in disease stage and leg circumference 
and increased quality of life associated with a programme 
comprising foot hygiene, bandaging, and use of socks and 
shoes. The second study was a randomised trial that used 
2% glycerine in the soaking water, with a primary outcome of 
skin barrier function. Neither of these studies assessed the 
incidence of acute dermatolymphangioadenitis. Several 
observational studies of patients with filarial lymphoedema 
have suggested the value of hygiene treatment in prevention 
of acute dermatolymphangioadenitis but, to our knowledge, 
no trial had been done.
Added value of this study
To our knowledge, this is the first randomised controlled trial 
to measure the effects of a lymphoedema management 
package on the most important consequence of podoconiosis, 
acute attacks of dermatolymphangioadenitis. Our study 
showed that pragmatic trials can be done in challenging, low-
resource settings with high rates of follow-up, and that acute 
attacks are more frequent among untreated patients than 
previously thought.
Implications of all the available evidence
Simple limb hygiene and foot care measures are effective 
in preventing acute dermatolymphangioadenitis in 
podoconiosis lymphoedema. These findings are likely to 
inform guidelines for elimination of podoconiosis in 
endemic countries.
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older, had a diagnosis of at least stage 2 podoconiosis 
(persistent lymphoedema)26 and a negative BinaxNOW 
Filariasis rapid antigen test (Alere Inc, Waltham, MA, 
USA), and intended to remain within Aneded woreda for 
the duration of the trial. These part icipants were identified 
by Health Extension Workers, who listed potential 
patients.27 Participants were excluded if they had a mental 
or physical disability or disease that would impair their 
ability to adhere to the intervention, such as a nodular 
disease preventing use of shoes. We intended for these 
patients to be representative of the population of people 
with podoconiosis in Amhara, northern Ethiopia, where 
the prevalence of podo coniosis in adults was estimated to 
be 3·9% in the 2013 nationwide mapping.28
The trial was done in accordance with the Helsinki 
Declaration and the International Conference on 
Harmonisation Good Clinical Practice guidelines and was 
approved by the Institutional Review Board of the College 
of Health Sciences, Addis Ababa University (071/13/SPH), 
the National Ethical Review Committee of the Ethiopian 
Science and Technology Agency (3­1/794/06), the Food, 
Medicine and Health Care Administration Authority of 
Ethiopia (02/6­1/05/39), and the Research Ethics and 
Governance Committee of Brighton and Sussex Medical 
School (13/107/DAV). Participants gave informed consent 
and either signed the consent form themselves or, 
if unable to write, added thumbprints that were 
countersigned by an independent witness.
Randomisation and masking
We randomly allocated patients (at a 1:1 ratio) to either the 
intervention group (who received instructions for foot 
hygiene, skin care, bandaging, exercises, and use of socks 
and shoes, and support by lay Community Podoconiosis 
Agents at monthly meetings) or the control group (who 
received no intervention). Computer­based individual 
randomisation was done at the KEMRI Wellcome Trust 
Research Programme Clinical Trials Facility in Kilifi, 
Kenya, by use of enrolment lists sent by the trial data 
manager (MM) to the trial statistician (GF; who had no 
other involvement in the trial). This randomisation was 
done by use of the ralloc command in STATA version 14. 
The process of assignment to treat ment groups was 
masked from the statisticians per forming the analyses 
(MN and JAB), but an individual patient’s group status 
could not be masked to the field team and participants 
were aware of their allocation. However, the researchers 
doing all analyses were masked to treatment groups.
Procedures
The intervention consisted of monthly group meet­
ings with instruction and practical demonstration of 
lymphoedema management by Community Podoconiosis 
Assistants (locally appointed women, who were given 
2 weeks of training), to support daily self­treatment. 
Lymphoedema management comprised foot hygiene 
(soaking the feet, washing with bathroom soap with a 
pH lower than 9 to minimise the effects of this soap on 
skin barrier function, rinsing with clean water, drying, 
and applying emollient) and foot care (supervised use of 
single­layer, non­elastic bandages for disease stages of at 
least 3; foot and calf exercises; instruction to practise 
foot hygiene daily at home, to elevate the foot of the bed 
or sleeping area, and to use socks and shoes during 
waking hours; provision of shoes and socks at month 3, 
when the most easily reversible oedema had subsided). 
Patients in the control group were told that they were on 
a waiting list for treatment, to start 12 months later, and 
were not given the instructions or demonstrations that 
the intervention group received. Scheduled follow­up 
visits for data collection were made 3, 6, 9, and 12 months 
after study initiation by data collectors who were 
independent of the Community Podoconiosis Assistants. 
Patients in the control group were visited on different 
days and at different sites to those in the intervention 
group, to minimise spillover.
Patients in both groups were trained to record episodes 
of acute dermatolymphangioadenitis in monthly pictorial 
diaries that were specifically developed for the study and 
validated against assessment by health professionals. 
The feasibility of diary completion and the validity of self­
reports of acute dermatolymphangioadenitis against 
diagnosis by health workers had also been checked in a 
small pilot study before the trial.29 The positive predictive 
value of patients’ self­reports of episodes of acute 
dermatolymphangioadenitis was 0·87.
Outcomes
The primary outcome was cumulative incidence of 
episodes of acute dermatolymphangioadenitis in all 
patients with available data from treatment initiation 
until up to 12 months of follow­up, compared between 
intervention and control groups. Second ary outcomes 
were foot care behaviours (foot washing, use of oint ment, 
use of bandages, elevation, exercises, use of socks and 
shoes), measured by questionnaire of both groups at 
baseline and 12 months; clinical outcomes (clinical stage 
of disease, lower leg and foot circum ferences, presence 
of mossy changes, wounds and interdigital lesions, 
duration of acute dermato lymphangioadenitis days); 
social out comes (quality of life, perceived stigma); and 
economic productivity. Social and economic outcomes 
will be reported in a future publication. The outcomes 
recorded at each visit are shown in the appendix; 
prespecified interactions between age, sex, and kebele 
location and the main effects were calculated with 
likelihood ratio tests. Adverse events were reported on 
the case record forms completed by the data collectors at 
the quarterly home visits.
During the trial team’s pre­study visit, the staff 
providing treatment in nearby districts reported that 
affected people rarely adopted the lymphoedema 
manage ment package, even if they saw it in use in their 
village. These reports persuaded us to use individual 
See Online for appendix
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rather than cluster randomisation, although we decided 
not to randomise more than one patient per household. 
Given that patients within the same subdistricts could be 
allocated to different groups, we also examined for 
possible use of the intervention measures in the control 
group through reported behavioural practices at baseline 
and month 12 in case report forms.
Statistical analysis
We estimated that 340 participants in each group would 
give 90% power to detect a reduction in frequency of 
acute dermatolymphangioadenitis episodes of 28% (from 
5·6 to 4·0 episodes per year), given a mean 
baseline incidence of acute dermatolymphangioadenitis 
of 5·6 (SD 4·9) episodes per year,16 an α of 0·05, an ability 
to examine the effects of up to four confounders, and 
15% dropout.20 A statistical analysis plan was reviewed 
and agreed by the Trial Steering Committee before 
locking and unmasking the database. No interim analysis 
was planned or done. We analysed the primary outcome 
in all participants assigned to the intervention or control 
groups who completed diaries at 3, 6, 9, and 12 months. 
The incidence of new acute dermatolymphangioadenitis 
episodes was defined as the number of episodes, divided 
by the total duration of observation for each participant. 
We examined whether treatment outcome differed by 
sex, by disease severity at baseline, or by kebele location. 
For kebele location, we created two groups: close 
(nine kebeles) and remote (nine kebeles), and tested for 
group effect modification on the study outcome with a 
likelihood ratio test. We calculated the duration of 
observation for each participant until the trial conclusion, 
death, or dropout. We compared the incidence ratios of 
patients in the intervention group with those in the 
control group using Poisson regression with robust 
standard errors, to allow for clustering of events 
within participants. The duration of episodes of acute 
dermato lymphangioadenitis was computed by adding 
the duration of all episodes in days and dividing by the 
number of days of observation for each participant, 
and these durations were compared with a rank sum 
test. Other secondary outcomes will be reported in a 
future publication. Analysis was done by an intention­
to­treat protocol. STATA was used for all statistical 
analyses. No Data Safety and Monitoring Committee was 
needed, since the intervention is publicly available, 
commonly used, and safe. The trial is registered with the 
International Standard Randomised Controlled Trials 
Number Register, number ISRCTN67805210.
Role of the funding source
The funders of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report. 
The study design was altered (from a stepped­wedge 
design to an individually randomised trial) before 
funding of the proposal, in accordance with comments 
from reviewers who acted on behalf of the joint funders. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between Dec 1, 2014, and June 30, 2015, 1339 pa tients 
with podoconiosis were screened for eligibility; 
696 patients were enrolled and 643 were excluded (figure). 
350 study participants were randomly assigned to the 
intervention group and 346 to the control group. 
46 (7%) patients did not complete the study. 29 patients 
(4% of all patients enrolled; 63% of non­completers) 
dropped out in the intervention group and 17 (2%; 37%) Figure: Trial profile
1339 patients screened for eligibility 
696 enrolled and randomly assigned
346 assigned to control group 
340 followed up at month 3
337 followed up at month 6
334 followed up at month 9
329 followed up at month 12
6 discontinued
2 died
4 voluntary withdrawals
3 discontinued
1 died
2 voluntary withdrawals
3 discontinued
3 died
5 discontinued
3 died
2 voluntary withdrawals
350 assigned to intervention group 
335 followed up at month 3
331 followed up at month 6
326 followed up at month 9
321 followed up at month 12
15 discontinued
5 died
7 voluntary withdrawals
1 protocol deviation
1 lost to follow-up
1 other
5 discontinued
3 died
1 voluntary withdrawals
1 protocol deviation
4 discontinued
1 died
3 voluntary withdrawals
5 discontinued
1 died
4 voluntary withdrawals
643 ineligible 
551 had stage 1 disease 
70 did not attend health check 
3 did not give consent 
19 other reasons 
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dropped out in the control group (p=0·07). At the end of 
the study (after 12 months), 321 (92%) of 350 patients in 
the intervention group and 329 (95%) of 346 patients in 
the control group remained in the trial (figure). 
Table 1 shows the baseline characteristics of the study 
groups. The median age (IQR) of the study participants 
was 50 (40–61) years. Only 19% of participants had 
any formal education. WHO Disability Assessment 
Schedule­II scores, 30 total stigma scores on the validated 
podoconiosis stigma scale,31 Dermatology Quality of Life 
Index scores,11 and clinical measures (episodes of acute 
dermatolymphangioadenitis in the previous month, 
disease stage, presence of mossy lesions, and lower leg 
and foot circumferences) were similar between groups. 
During the 12 months of follow­up, 16 550 episodes of 
acute dermatolymphangioadenitis within 765·2 person­
years were recorded, giving an overall incidence of 
21·6 episodes per person­year (95% CI 21·3–21·9) across 
both groups (table 2). Overall, there were 7515 episodes 
in the intervention group during 387·1 person­years, 
and 9035 episodes in the control group during 
378·1 person­years, giving an incidence of 19·4 episodes 
per person­year (18·9–19·9) in the inter vention group 
and 23·9 episodes per person­year (23·4–24·4) in the 
control group. The incidence rate ratio of the intervention 
group relative to the control group was therefore 0·81 
(0·74–0·89; p<0·0001), with a difference of –4·5 episodes 
per person­year (–5·1 to –3·8). 
We found that the intervention had increasing efficacy in 
reducing the risk of acute dermatolymphangioadenitis 
episodes over time (p=0·0012 between the quarterly 
intervals; table 2). Although there was no difference in the 
incidence of acute dermatolymphangioadenitis episodes by 
sex at baseline (p=0·10), we also found greater efficacy of 
the intervention in men than women; women had a higher 
incidence of acute dermatolymphangioadenitis episodes 
and higher ratio of acute dermato lymphangioadenitis 
incidence relative to the control group than did men (both 
p<0·0001; table 3). Age at enrolment to the trial did not 
significantly modify the effect of the intervention (p=0·114; 
appendix). The number of participants living in kebeles 
close to or remote from the surfaced road did not differ 
between the intervention and control groups (p=0·67). 
However, kebele location affected intervention efficacy: the 
incidence rate ratio was 0·91 (95% CI 0·82 to 1·02) in 
participants from the nine closer kebeles and 0·59 
(0·49 to 0·72) in those from the nine more remote kebeles 
(p=0·0003).
Adherence by participants to the trial intervention was 
consistently above 85% for washing their feet and lower 
legs with soap, applying ointment, use of bandages, 
elevation, and exercise during the 12 months of the study 
(table 3). However, adherence to instructions to wear socks 
and shoes was lower, even after the first 3 months, when 
custom shoes had been supplied (appendix). There was no 
evidence that adherence to the overall intervention (p=0·79) 
or any specific elements (p>0·05; table 3) varied by sex.
The duration of acute dermatolymphangioaden­
itis episodes ranged from 1 to 35 days, with a higher 
geometric mean in the control group than the 
intervention group (p<0·001; table 4). 2915 (17·6%) of the 
16 550 acute dermatolymphangioadenitis episodes lasted 
for 1 day, comprising 1463 (19%) of 7515 episodes in the 
intervention group and 1452 (16%) of 9035 episodes 
in the control group (p<0·0001). The geometric mean 
duration of acute dermatolymphangioadenitis episodes 
per year was 18·9 (95% CI 18·6 to 19·2) days in the 
intervention group and 25·6 (95% CI 15·2 to 26·0) days 
in the control group (p<0·0001).
No serious adverse events were related to the inter­
vention or intervention products. Of the 19 deaths during 
the trial, ten (53%) occurred in the intervention group 
and nine (47%) in the control group (p=0·84). Nine of 
the patients who died were men and ten were women.
In the analysis of potential spillover (contamination), 
both groups of patients reported increased frequency of 
washing their feet, of washing their feet with soap, and of 
applying ointment (table 5), although the increases in 
Intervention 
group (n=350)
Control group 
(n=346)
Age, years 50 (40–60) 52 (41–65)
Women 172 (49%) 164 (47%)
Married 226 (65%) 226 (65%)
Ever attended school 66 (19%) 66 (19%)
Asset index quintile 1* 77 (22%) 75 (22%)
Own shoes 219 (63%) 231 (67%)
Own socks 76 (22%) 64 (18%) 
Use soap to wash their feet 198 (57%) 186 (54%)
Use ointment on their feet 110 (31%) 128 (37%)
Ever had acute 
dermatolymphangioadenitis
341 (97%) 341 (99%)
Number of acute 
dermatolymphangioadenitis 
episodes in past 30 days
2 (2–3) 3 (2–3)
Average duration of the latest 
episode, days
3 (3–5) 3 (3–5)
Mossy lesions present on either 
leg
184 (53%) 185 (53%)
Interdigital lesions present on 
either leg
89 (25%) 95 (27%)
Right lower leg circumference, cm 23 (21–27) 24 (22–27)
Left lower leg circumference, cm 24 (22–26) 24 (22–26)
Left foot circumference, cm 25 (24–27) 25 (24–27)
Right foot circumference, cm 25 (24–27) 25 (24–27)
Total WHO Disability Assessment 
Schedule II score30
35 (28–39) 34 (25–39)
Total stigma score31 18 (12–21) 17 (12–21)
Total Dermatology Quality of Life 
Index11
21 (14–32) 21 (14–31)
Data are n (%) or median (IQR). *Asset index derived by use of principal 
component analysis, and these data indicate participants in the poorest 20% of 
the asset index.
Table 1: Baseline characteristics
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these behaviours were significantly smaller in the control 
group (p<0·001).
Discussion
To our knowledge, GoLBeT is the first trial to assess the 
effects of a lymphoedema management package on 
the most important clinical consequence of podocon­
iosis lymphoedema: the incidence of acute dermato­
lymphangio adenitis episodes. Our trial showed a clear 
effect of the intervention, with an overall incidence 
ratio of 0·81, and evidence of cumulative benefit over 
time. Baseline incidence of acute dermato lymphangio­
adenitis and in cidence rate in the control group during 
the trial were similar to those reported in western 
Ethiopia in 2016,15 but much higher than those reported 
in northern Ethiopia in 2012 (and used to calculate the 
sample size) for this trial,14 highlighting how little was 
previously known about this important sequela. The 
reduction in incidence is smaller than the reduction 
shown in uncontrolled prospective studies among 
patients with lymphatic filariasis in Haiti,24 Burkina 
Faso,32 and Odisha state, India,22 where reductions 
ranged from 33% to 69%. A meta­analysis33 of hygiene­
based lympho edema management in lymphatic filariasis 
showed an acute dermatolymphangioadenitis incidence 
ratio of 0·32 (95% CI 0·25–0·40) across the eight studies 
with sufficient (non­randomised) information from 
before and after treatment. The smaller reduction 
measured in our trial compared with these previous 
studies might reflect a different disease process, the 
greater stringency of a randomised controlled trial, 
spillover (contamination)34 across randomisation groups, 
or different methods of gathering primary outcome data. 
This difference in results also indicates that use of a 
simple package is one approach to preventing acute 
dermatolymph angioaden itis, but that more research is 
needed to identify other approaches.
The reported increased frequency of foot washing, of 
washing feet with soap, and of applying ointment in both 
groups suggest a Hawthorne effect35 (when simply being 
studied alters behaviour) that could have driven spill­
over. Together, these influences are likely to have re­
duced the observed magnitude of the difference in 
incidence of acute dermatolymphangio adenitis episodes 
between groups.
Primary outcome data were gathered through monthly 
self­reported diaries, which were supported by one 
researcher­administered question in the quarterly case 
report form. Previous validation of self­reports of acute 
dermatolymph angioadenitis episodes by use of the trial 
diaries gave a positive predictive value of 0·87 when 
compared with diagnoses by health professionals.29 The 
false­positive self­reports are likely to represent 
conditions that are not amenable to foot hygiene 
treatment, so it is possible that the actual effect of this 
treatment package on acute dermatolymphangioadenitis 
was larger than we measured. Given our concern with 
altering the behaviour of patients in the control group, 
contact with these patients (and diary collection) only 
occurred every 3 months, rather than monthly (as for 
patients in the intervention group). Diaries were always 
carefully checked when they were collected, but it is 
possible that the lower frequency of collection in the 
control group led to bias through fewer episodes being 
reported in this group.
Intervention group (n=350) Control group (n=346) Incidence ratio 
(95% CI)*
Incidence 
difference (95% CI)
Person-years Number 
of events
Incidence† (95% CI) Person-years Number 
of events
Incidence† (95% CI)
Overall 387·1 7515 19·4 (18·9–19·9) 378·1 9035 23·9 (23·4–24·4) 0·81 (0·74 to 0·89) –4·5 (–5·1 to –3·8)
Q1 102·3 1227 12·0 (11·3–12·7) 102·1 1642 16·1 (15·3–16·9) 0·75 (0·63 to 0·88) –4·1 (–5·1 to –3·1)
Q2 100·1 2492 24·9 (23·9–25·9) 100·0 2903 29·0 (27·9–30·1) 0·86 (0·77 to 0·95) –4·1 (–5·6 to –2·7)
Q3 97·5 2182 22·4 (21·5–23·3) 96·9 2555 26·4 (25·3–27·4) 0·85 (0·78 to 0·94) –4·0 (–5·4 to –2·6)
Q4 87·2 1614 18·5 (17·6–19·4) 79·0 1935 24·5 (23·4–25·6) 0·76 (0·66 to 0·86) –6·0 (–7·4 to –4·6)
*Calculated by use of Poisson regression, to account for participant clustering of events. †Episodes per person-year.
Table 2: Incidence of episodes of acute dermatolymphangioadenitis, overall and by quarter
Overall (n=350) Men (n=178) Women (n=172) p value
Incidence of acute 
dermatolymphangioadenitis 
episodes* (95% CI)
21·6 (21·3–21·9) 20·9 (20·4–21·3) 22·4 (21·9–22·9) <0·0001
Ratio of acute 
dermatolymphangioadenitis 
incidence, intervention to 
control groups (95% CI)
0·81 (0·69–0·96) 0·73 (0·64–0·84) 0·90 (0·79–1·02) <0·0001
Adherence
To overall intervention 95·4% (94·6–96·1) 95·4% (94·7–96·1) 95·3% (94·4–96·1) 0·79
To washing with soap 98·6% (98·2–99·1) 98·5% (97·9–99·0) 98·9% (98·4–99·3) 0·27
To applying ointment 98·0% (97·4–98·8) 97·9% (97·2–98·6) 98·2% (97·5–99·0) 0·48
To leg elevation 97·4% (96·3–98·4) 97·7% (96·9–98·5) 97·0% (95·7–98·3) 0·34
To exercises 97·3% (96·4–98·2) 97·6% (96·8–98·3) 97·0% (96·0–98·1) 0·40
To wearing socks 87·2% (84·8–89·5) 87·1% (84·9–89·3) 87·2% (84·7–89·6) 0·98
To wearing shoes 93·6% (92·4–94·9) 93·8% (92·7–95·0) 93·4% (92·1–94·7) 0·60
Data are mean proportion (95% CI), unless otherwise indicated. These data are based on adherence records collected 
from participants in the intervention group only, which are from reported data from the previous month (at 3, 6, 9, 
and 12 months). *Episodes per person-year. 
Table 3: Incidence of acute dermatolymphangioadenitis episodes and adherence, stratified by sex
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An earlier uncontrolled follow­up of patients who were 
offered a similar lymphoedema management package 
suggested slightly greater improvement in clinical 
outcomes among men than women.20 This trial was 
therefore powered to enable subanalysis by sex; we also 
found a significantly greater effect of this package among 
men (20·9 episodes per person­year among men vs 
22·4 episodes per person­year among women). We found 
no difference in frequency of baseline acute dermato­
lymphangioadenitis episodes by sex (p=0·10; data not 
shown), and there was no evidence of any difference in 
adherence overall or to specific intervention components 
by sex. To our knowledge, studies33 of lymphoedema 
management in patients with lymphatic filariasis have not 
disaggregated data by sex so it is difficult to contextualise 
this finding. Observational studies14,36 among people with 
podoconiosis suggest that men have more access to shoes, 
and are more likely to own a pair. In the general population, 
men are more likely to be found wearing shoes at 
interview.37 However, sex­related differences in access to 
foot hygiene treatment have not been documented.38 The 
most robust studies37 on podoconiosis prevalence showed 
that more women than men were affected in Ethiopia. Our 
findings underscore the importance of ensuring gender 
equity in provision, uptake, and effects of lympho edema 
management services.
We found evidence of effect modification by location: 
participants in more remote kebeles recorded a greater 
effect of the treatment package than those in kebeles 
closer to the surfaced road. This finding could not be 
explained by differences in baseline disease severity 
(remote vs close kebeles: p=0·19, left leg disease stage; 
p=0·39, right leg disease stage) or access to water for 
washing (p=0·09). We anticipate that the results of our 
qualitative process assessment could enable us to better 
interpret this interaction.
We have found clinically important and significant 
reductions in incidence of acute dermatolymphan­
gioadenitis episodes, episode duration, and days with 
acute dermatolymphangioadenitis symptoms after ad­
min istration of a lymphoedema management package 
com pared with no intervention. In the intervention 
group, the proportion of acute attacks that lasted only a 
single day was significantly higher, and the total duration 
of acute attacks was significantly lower than in the control 
group (table 4). These findings suggest that the foot 
hygiene package might shorten attacks and prevent their 
occurr ence. In two studies39,40 of patients with lymphatic 
filariasis, duration of acute dermatolymphangioadenitis 
also de creased with foot care, and the magnitude of the 
change was similar to our findings among people with 
podoconiosis lymphoedema. Shorter duration of acute 
dermato lymphangioadenitis might have also been re­
flected in the number of days in the past month 
dur ing which patients were unable to carry out their 
usual activities, which was significantly fewer in the 
intervention group.
GoLBeT achieved a very high proportion of patients who 
completed follow­up (92% in the intervention group, 
95% in the control group) given the remote setting of 
many of the kebeles and difficulties in seasonal access. 
This proportion was considerably higher than that 
assumed when calculating the necessary sample size 
(85%), and seems to have been the consequence of 
employing retention strategies (as advised in the Rapid 
Ethical Assessment;41 for example, patients in the control 
group were given small packs of coffee at data collection 
visits), relationship­building between patients and the trial 
team, and determined fieldwork.
Given the nature of the intervention, full masking was 
not possible in this trial. Patients were aware of their 
randomisation status. The duties and responsibilities of 
data collectors were independent of those delivering 
treatment, but they might have been able to guess the 
participant’s group if they saw the supplies required 
for treatment.
Intervention 
group (n=350)
Control group 
(n=346)
p value
Duration of episodes of acute 
dermatolymphangioadenitis, 
geometric mean days 
(95% CI)
2·1 (2·0–2·4) 2·3 (2·2–2·4) <0·0001
Total duration of symptoms 
of acute 
dermatolymphangioadenitis, 
median days (IQR)
96 (54–129) 116 (80–154) <0·0001
Total duration of symptoms 
of acute 
dermatolymphangioadenitis 
per person-year, median days 
(IQR)
22 (12–30) 26 (17–36) <0·0001
Table 4: Duration of acute dermatolymphangioadenitis symptoms
Intervention 
group (n=350)
Control group 
(n=346)
p value
Washed feet last night?
Baseline 307 (88%) 298 (86%) 0·54
Month 12 319 (91%) 317 (92%) 0·02*
How many times in the past week did you wash your feet?
Baseline 223 (64%) 218 (63%) 0·85
Month 12 291 (83%) 277 (80%) 0·29
How many times in the past week did you wash your feet with soap?
Baseline 39 (11%) 42 (12%) 0·68
Month 12 242 (69%) 140 (40%) <0·0001
Over the last month, have you put any ointment on your feet?
Baseline 111 (32%) 128 (37%) 0·16
Month 12 259 (74%) 160 (46%) <0·0001
Group data are number of affirmative responses (%) or number that answered “at 
least seven times” (%). Data are based on reports by all patients at baseline and at 
12 months and refer to their behaviours during the past week. p value data are 
from a χ² test, or *Fisher’s exact test. 
Table 5: Participant answers to questions on behavioural practices by 
intervention group
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The trial setting meant that, although adverse events 
were reported at each data collection visit, passive reporting 
was slow and some adverse events might have been 
missed. Although patients, their families, Community 
Podoconiosis Assistants, and data collectors were asked to 
report adverse events immediately, immediate reporting 
was difficult in practice. Patients and relatives were also 
asked to notify the receiving doctor of their participation in 
the trial if they were an outpatient or inpatient at the 
district hospital. Receiving doctors were given an 
information session about the trial and asked to contact 
the trial coordinator immediately if a participant consulted 
them. The number of days between death and report 
reaching the Trial Coordinator ranged from less than 1 day 
to 28 days (for one incident). Once reported to the trial 
team, all adverse events were reported on the same day to 
the Local Safety Monitors by telephone and were followed 
up with an email when the serious adverse event form had 
been completed. Although no serious adverse events were 
considered to be related to the intervention products, it is 
possible that we missed some minor adverse events.
GoLBeT was pragmatic in terms of the setting in which 
it was done: patients were offered treatment in their 
communities, which were remote, and vehicle access was 
often difficult. The intervention took the form of supported 
self­management; daily self­care was supported by monthly 
group meetings that reinforced technique and replenished 
treatment supplies. Our trial is a good example of rigorous 
evaluation of a frugal innovation—ie, a low­tech approach 
to solve unmet local needs.19 Although we have shown that 
this management package is effective, wider adoption by 
government and non­government stakeholders depends 
not only on effectiveness, but also on cost, acceptability, 
and sustainability. We anticipate that a process evaluation 
done during the closing stages of this trial will shed further 
light on acceptability, feasibility, and sustainability, and 
cost­effectiveness will be presented separately after further 
analyses are completed. The message for national policy 
makers is clear: adoption of a simple lymphoedema 
management package is effective against incidence and 
duration of acute dermatolymph angioadenitis, the most 
disabling consequence of podoconiosis.
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